Apogee Therapeutics, Inc.
APGE
Jodie situation report
Apogee Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 8 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as BMRN begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind APGE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
WXILYFiling-linked namepartnerMay 11, 2026 ▾
“We are also obligated to pay royalties to (i) Paragon at a royalty rate of a low single-digit percentage based on net sales of any products under the License Agreements, once commercialized and (ii) WuXi Biologics at a royalty rate of a fraction of a single d…”
Depended on by
NKTRNektar TherapeuticscompetitorMay 8, 2026 ▾
“In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Symbiotix, LLC, Apogee Therapeutics, Janssen, AstraZeneca and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therape…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
APGE is currently a Leader in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.